AMST — what changed in the latest 10-K

Text added vs the prior filing · source: 10-K · 2026-09-23

• Amesite is a technology company focused on building and commercializing AI (artificial intelligence)-powered solutions for the enterprise and for professionals, with particular emphasis on the post-acute healthcare market. In fiscal 2026, we launched a census-based Enterprise tier with EMR (electron…

• We operate through two product lines: NurseMagic™ and LynkMagic™. NurseMagic™ solutions include a B2B (business-to-business) enterprise application and a B2C (business-to-consumer) solution for individual healthcare professionals. LynkMagic™ provides enterprise AI solutions for healthcare and relate…

• In fiscal 2026, Amesite’s sales and marketing activities focused on increasing adoption of NurseMagic™ among individual healthcare professionals and enterprise customers, while supporting the introduction of LynkMagic™ enterprise solutions. We emphasized digital marketing, self-service onboarding, a…

• The Company was incorporated in November 2017 and is listed on the Nasdaq Capital Market under the trading symbol “AMST”.

Text removed vs the prior filing · source: 10-K · 2025-09-29

• Amesite is a technology company focused on building and commercializing AI-powered solutions for the healthcare sector, with particular emphasis on the post-acute care market. In fiscal 2025, we completed our pivot from an education-centric model to one firmly anchored in the demands and opportuniti…

• We operate through two product lines under our NurseMagic™ brand: a B2C (direct-to-practitioner) app and a B2B (enterprise) platform. These solutions directly address operational, compliance, and efficiency challenges faced by healthcare professionals and organizations.

• In FY 2025, Amesite’s sales and marketing approach centered on high-velocity onboarding, delivery of scalable product tiers, and digital-first brand building. Amesite’s sales and marketing strategy is crafted to maximize the reach and value of NurseMagic™ in healthcare, while maintaining flexibility…

• The Company was incorporated in November 2017. The Company is Amesite Inc. (Nasdaq: AMST) is a pioneering technology company specializing in the development and marketing of B2C and B2B AI-driven solutions, including its higher ed platform that offers professional learning. Leveraging its proprietar…

Text added vs the prior filing · source: 10-K · 2026-09-23

• Enforcement of federal and state laws regarding privacy and security of patient information may adversely affect our business, financial condition or operations.

• The use and disclosure of certain health care information by health care providers and their business associates have come under increasing public scrutiny. Recent federal standards under the Health Insurance Portability and Accountability Act of 1996, or HIPAA, establish rules concerning how indivi…

Text removed vs the prior filing · source: 10-K · 2025-09-29

• We are an “emerging growth company” and can avail ourselves of reduced disclosure requirements applicable to emerging growth companies, which could make our common stock less attractive to investors.

• We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and we have elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” …

Text added vs the prior filing · source: 10-K · 2026-09-23

• We generated revenues of $364,777 for the year ended June 30, 2026 as compared to $110,459 for the year ended June 30, 2025. Revenue was primarily from B2B license fee revenues related to the NurseMagicTM app.

• We have undertaken a strategic pivot aimed at growing our customer base while reducing risk and losses, resulting in a larger client base and a dramatic reduction in cash burn.

• General and administrative expenses for the year ended June 30, 2026 were relatively consistent at $2,510,264 as compared to $2,477,888 for the year ended June 30, 2025.

• On April 28, 2026, we closed on a registered direct offering of 696,866 shares of common stock at a purchase price of $1.435 per share, a concurrent private placement of pre-funded warrants to purchase 696,866 shares of common stock and common warrants to purchase an aggregate of 2,787,464 shares of…

• The following table summarizes our cash flows for the fiscal years ended June 30, 2026 and 2025:

Text removed vs the prior filing · source: 10-K · 2025-09-29

• We generated revenues of $110,459 for the year ended June 30, 2025 as compared to $166,881 for the year ended June 30, 2024. Revenue compared to the prior year was primarily from license fee revenues related to the NurseMagicTM app.

• We have strongly pivoted to grow our customer base while reducing risk and losses, resulting in a larger client base, a short-term reduction in overall revenue and a dramatic reduction in cash burn. Larger, cash-upfront deals were struggling to produce sustainable revenue, as administrative barriers…

• General and administrative expenses for the year ended June 30, 2025, were $2,477,888 as compared to $2,908,289 for the year ended June 30, 2024. The decrease of $430,401 is primarily due to significant savings in the areas of employee payroll and Board of Directors compensation due to the resignati…

• During the period from November 14, 2017 (date of incorporation) to September 30, 2020, we raised net proceeds of approximately $11,760,000 from private placement financing transactions (stock and debt). On September 25, 2020, we completed the Offering of 250,000 shares of our common stock, $0.0001 …

• On August 2, 2021, we entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), under which, subject to specified terms and conditions, we may sell up to $16.5 million of shares of common stock. Our net proceeds under the Purchase Agreement wi…